Zealand Pharma A/S American Depositary Shares
ZEAL
ZEAL was delisted on the 29th of September, 2022.
13 hedge funds and large institutions have $62.2M invested in Zealand Pharma A/S American Depositary Shares in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
31% more capital invested
Capital invested by funds: $47.6M → $62.2M (+$14.7M)
18% more funds holding
Funds holding: 11 → 13 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$1.04M |
| 2 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$335K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$310K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$257K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$8.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$35.6K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$20K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$20K |
| 4 |
Morgan Stanley
New York
|
-$8.16K |
ZEAL Hedge Fund Activity: Q2 2019 in Review
13 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Zealand Pharma A/S American Depositary Shares (ZEAL) for Q2 2019, worth a combined $62.2M — up 31% from $47.6M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ZEAL positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $1.04M. The largest seller was UBS Group, cutting an estimated $35.6K.
- 13 institutional investors held Zealand Pharma A/S American Depositary Shares (ZEAL) as of Q2 2019, up from 11 in Q1 2019.
- Funds reported $62.2M of Zealand Pharma A/S American Depositary Shares stock for Q2 2019, up 31% quarter-over-quarter.
- 3 funds opened new Zealand Pharma A/S American Depositary Shares positions in Q2 2019 and 1 closed out, a net change of +2 holders.
- The largest Zealand Pharma A/S American Depositary Shares buyer in Q2 2019 was Farallon Capital Management, an estimated $1.04M added.
- The largest Zealand Pharma A/S American Depositary Shares seller in Q2 2019 was UBS Group, an estimated $35.6K sold.
Based on aggregated 13F filings for Q2 2019.